FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 359:1287-1289 September 18, 2008 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Yusuf, S. Related Article by Sacco, R. L. PubMed Citation

If clinical trials were sporting contests, then it would be fair to say that low-dose aspirin plus extended-release dipyridamole (Aggrenox) was the clear favorite against clopidogrel going into the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial (ClinicalTrials.gov number, NCT00153062 [ClinicalTrials.gov] ). The trial, reported on in this issue of the Journal by Sacco et al.,¹ tested these two antiplatelet agents for secondary stroke prevention in their first head-to-head contest.

In two previous large randomized clinical trials enrolling patients after stroke (the European Stroke Prevention Study 2 [ESPS2]² and the European/Australasian Stroke Prevention in Reversible Ischemia Trial³ [ESPRIT, NCT00161070 [ClinicalTrials.gov] ]), . . . [Full Text of this Article]

Source Information

From the Institute for Clinical Research and Health Policy Studies (D.M.K.) and the Departments of Medicine (D.M.K.) and Neurology (D.E.T.), Tufts Medical Center, Tufts University School of Medicine, Boston.

This article (10.1056/NEJMe0806806) was published at www.nejm.org on August 27, 2008.

This article has been cited by other articles:

• Selim, M. (2009). Antiplatelets for Stroke Prevention: Implications of the PRoFESS Trial. Stroke 40: 1936-1937 [Full Text]  
• (2008). Antiplatelet Agents to Prevent Recurrent Stroke. JWatch Oncology and Hematology 2008: 2-2 [Full Text]